Author

E. He

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:genetic perturbation / CRISPR· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

F. Zhang· 2 shared G. Wang· 2 shared R. D. Chow· 2 shared S. Chen· 2 shared L. Zhu· 1 shared M. Majety· 1 shared Q. Han· 1 shared Y. Zhang· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

8 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

F. Zhang

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Multiplexed inhibition of immunosuppressive genes with Cas13d for on-demand combinatorial cancer immunotherapy

F. Zhang, G. Wang, R. D. Chow, E. He, M. Majety, Y. Zhang, S. Chen

This paper develops MUCIG, a CRISPR-Cas13d-based method to silence multiple immunosuppressive genes in the tumor microenvironment, showing efficacy in preclinical models.

bioRxiv · Mar 14, 2023Immunology

Rational design of immune gene therapy combinations via in vivo CRISPR activation screen of tumor microenvironment modulators

G. Wang, F. Zhang, R. D. Chow, E. He, L. Zhu, Q. Han, S. Chen

This study uses in vivo CRISPR activation screens to identify immunostimulatory factors that enhance anti-tumor immunity and develop effective gene therapy combinations.

bioRxiv · Mar 14, 2023 · PreprintImmunology